Discovery of 1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-ones based novel, potent and PI3Kδ selective inhibitors was written by Bahekar, Rajesh;Dave, Bhushan;Soman, Shubhangi;Patel, Dipam;Chopade, Rajendra;Funde, Radhika;Kumar, Jeevan;Sachchidanand, S.;Giri, Poonam;Chatterjee, Abhijit;Mahapatra, Jogeswar;Vyas, Purvi;Ghoshdastidar, Krishnarup;Bandyopadhyay, Debdutta;Desai, Ranjit C.. And the article was included in Bioorganic & Medicinal Chemistry Letters in 2019.Recommanded Product: 1-(2-Bromoethyl)-4-methoxybenzene This article mentions the following:
PI3Kδ is implicated in various inflammatory and autoimmune diseases. For the effective treatment of chronic immunol. disorders such as rheumatoid arthritis, it is essential to develop isoform selective PI3Kδ inhibitors. Structure guided optimization of an imidazo-quinolinones based pan-PI3K/m-TOR inhibitor (Dactolisib) led to the discovery of a potent and orally bioavailable PI3Kδ isoform selective inhibitor (10h), with an improved efficacy in the animal models. In the experiment, the researchers used many compounds, for example, 1-(2-Bromoethyl)-4-methoxybenzene (cas: 14425-64-0Recommanded Product: 1-(2-Bromoethyl)-4-methoxybenzene).
1-(2-Bromoethyl)-4-methoxybenzene (cas: 14425-64-0) belongs to organobromine compounds. Most organobromine compounds, like most organohalide compounds, are relatively nonpolar. Commercially available organobromine pharmaceuticals include the vasodilator nicergoline, the sedative brotizolam, the anticancer agent pipobroman, and the antiseptic merbromin. Recommanded Product: 1-(2-Bromoethyl)-4-methoxybenzene
Referemce:
Bromide – Wikipedia,
bromide – Wiktionary